Roche has staked a claim to use its oral selective oestrogen receptor degrader (SERD) giredestrant as a second-line therapy for breast cancer, regardless of a patient's ESR1 mutation status. Top-line ...
AstraZeneca could become the first company to bring an oral selective oestrogen receptor degrader (SERD) drug to market as a first-line treatment for breast cancer after camizestrant hit the mark in a ...
The best label makers upgrade your organization efforts. I tested 13 digital and Bluetooth models for functionality, ease of ...
What do single-person home offices and multinational conglomerates have in common? Sooner or later, they all need a printer. Business-oriented printers designed to serve them span a huge array of ...
Can you chip in? This year we’ve reached an extraordinary milestone: 1 trillion web pages preserved on the Wayback Machine. This makes us the largest public repository of internet history ever ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback